Neutropenia inducida por adalimumab en un paciente con hidradenitis supurativa

Tumor necrosis factor alpha (TNF-α) inhibitors are used to treat several diseases. One of the most commonly used TNF-α inhibitors in children is adalimumab. Hematologic adverse events related to this therapy (thrombocytopenia, leukopenia, anemia, or thrombotic microangiopathy) are uncommon but may lead to high morbidity and mortality. 1,2 The case we report involves an 8-year-old girl born by cesarean delivery owing to symmetrical intrauterine growth restriction, with short stature, obesity, tricuspid regurgitation, developmental delay, steatohepatitis, and a family history of psoriasis. She had suffered inverted and plaque psoriasis since age 2 years. At 7 years old, in view

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neutropenia inducida por adalimumab en un paciente con hidradenitis supurativa

Cited by 2 publications

References 8 publications

Adalimumab

Adalimumab

Adalimumab‐induced hemolytic anemia in a girl with psoriasis

Contact Info

Product

Resources

About